228 related articles for article (PubMed ID: 34593608)
21. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional Circuitry of NKX2-1 and SOX1 Defines an Unrecognized Lineage Subtype of Small-Cell Lung Cancer.
Kong R; Patel AS; Sato T; Jiang F; Yoo S; Bao L; Sinha A; Tian Y; Fridrikh M; Liu S; Feng J; He X; Jiang J; Ma Y; Grullon K; Yang D; Powell CA; Beasley MB; Zhu J; Snyder EL; Li S; Watanabe H
Am J Respir Crit Care Med; 2022 Dec; 206(12):1480-1494. PubMed ID: 35848993
[No Abstract] [Full Text] [Related]
23. Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes.
Pongor LS; Schultz CW; Rinaldi L; Wangsa D; Redon CE; Takahashi N; Fialkoff G; Desai P; Zhang Y; Burkett S; Hermoni N; Vilk N; Gutin J; Gergely R; Zhao Y; Nichols S; Vilimas R; Sciuto L; Graham C; Caravaca JM; Turan S; Tsai-Wei S; Rajapakse VN; Kumar R; Upadhyay D; Kumar S; Kim YS; Roper N; Tran B; Hewitt SM; Kleiner DE; Aladjem MI; Friedman N; Hager GL; Pommier Y; Ried T; Thomas A
Cancer Discov; 2023 Apr; 13(4):928-949. PubMed ID: 36715552
[TBL] [Abstract][Full Text] [Related]
24. Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma.
Liu Y; Yin N; Wang X; Khoor A; Sambandam V; Ghosh AB; Fields ZA; Murray NR; Justilien V; Fields AP
Cell Rep; 2020 Jan; 30(3):771-782.e6. PubMed ID: 31968252
[TBL] [Abstract][Full Text] [Related]
25. Killing SCLC: insights into how to target a shapeshifting tumor.
Sutherland KD; Ireland AS; Oliver TG
Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
[TBL] [Abstract][Full Text] [Related]
26. In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer.
Szeitz B; Megyesfalvi Z; Woldmar N; Valkó Z; Schwendenwein A; Bárány N; Paku S; László V; Kiss H; Bugyik E; Lang C; Szász AM; Pizzatti L; Bogos K; Hoda MA; Hoetzenecker K; Marko-Varga G; Horvatovich P; Döme B; Schelch K; Rezeli M
Clin Transl Med; 2022 Sep; 12(9):e1060. PubMed ID: 36149789
[TBL] [Abstract][Full Text] [Related]
27. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
[TBL] [Abstract][Full Text] [Related]
28. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
29. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer.
Patel AS; Yoo S; Kong R; Sato T; Sinha A; Karam S; Bao L; Fridrikh M; Emoto K; Nudelman G; Powell CA; Beasley MB; Zhu J; Watanabe H
Sci Adv; 2021 Jan; 7(5):. PubMed ID: 33514539
[TBL] [Abstract][Full Text] [Related]
30. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
31. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
[TBL] [Abstract][Full Text] [Related]
32. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
[TBL] [Abstract][Full Text] [Related]
33. Nuclear factor I/B is an oncogene in small cell lung cancer.
Dooley AL; Winslow MM; Chiang DY; Banerji S; Stransky N; Dayton TL; Snyder EL; Senna S; Whittaker CA; Bronson RT; Crowley D; Barretina J; Garraway L; Meyerson M; Jacks T
Genes Dev; 2011 Jul; 25(14):1470-5. PubMed ID: 21764851
[TBL] [Abstract][Full Text] [Related]
34. Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer.
Fushimi A; Morimoto Y; Ishikawa S; Yamashita N; Bhattacharya A; Daimon T; Rajabi H; Jin C; Hagiwara M; Yasumizu Y; Luan Z; Suo W; Wong KK; Withers H; Liu S; Long MD; Kufe D
Mol Cancer Res; 2022 Sep; 20(9):1379-1390. PubMed ID: 35612556
[TBL] [Abstract][Full Text] [Related]
35. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
[TBL] [Abstract][Full Text] [Related]
36. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.
Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM
EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
39. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.
Kalari S; Jung M; Kernstine KH; Takahashi T; Pfeifer GP
Oncogene; 2013 Jul; 32(30):3559-68. PubMed ID: 22907430
[TBL] [Abstract][Full Text] [Related]
40. [Heterogeneity of small cell lung cancer: biological and clinicopathological implications].
Megyesfalvi Z; Bárány N; Valkó Z; Bugyik E; Paku S; Berta J; Lantos A; Fillinger J; Moldvay J; Bogos K; Rezeli M; Gálffy G; Lang C; Lohinai Z; Hécz R; Lovas T; Rényi-Vámos F; László V; Döme B
Magy Onkol; 2020 Sep; 64(3):243-255. PubMed ID: 34608895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
